Even if you count one-time restructuring costs of $7.3 million and a $15 million upfront payment to acquire rights to RHUCIN®, as unusual events, Santarus would have loss about $.06/share. And while Pharming plans to submit a Biologic License Application (BLA) to the FDA in December 2010 or January 2011 and a NDA is expected to be filed for Budesonide MMX in the 2nd half of 2011, neither drug candidate will have an affect on earnings near-term. The relaunch of Cycloset will help but many users just had their dosage change while the problems were resolved. Anyway, I look at it this quarterly report was a disaster.
News 
Market Data 
Discover 
